Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Hodgkin Lymphoma

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Treatment Selection and Sequencing Strategies in HER2+ Metastatic Breast Cancer 

Video Series

Treatment Selection and Sequencing in Third Line Settings and Beyond

Videos

Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options

Dr O’Shaughnessy leads a panel of medical experts in a discussion around a patient case surrounding findings from HER2CLIMB and EMILIA clinical trials.

Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.

Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection

Key opinion leaders discuss patient experiences with an oral chemotherapy regimen, highlighting benefits like treatment autonomy, challenges such as pill burden and gastrointestinal toxicities, and the importance of proactive side effect management and patient education.

Managing Oral Treatments and Patient Support Strategies in HER2+ mBC: Multidisciplinary Perspectives

Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases

Evolving Treatment Strategies in Early HER2+ Breast Cancer

Experts discuss how, there is a role for SRS in treating brain metastases such as if a patient were to have a large singular brain metastasis that is causing symptoms such as seizures of neurological decline, that SRS could be a warranted treatment.

Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS

Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.  

Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC

Treatment Selection and Sequencing in Third Line Settings and Beyond

EP: 1.Treatment Selection and Sequencing in Third Line Settings and Beyond

EP: 2.Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options

EP: 3.Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA

EP: 4.Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection

EP: 5.Managing Oral Treatments and Patient Support Strategies in HER2+ mBC: Multidisciplinary Perspectives

EP: 6.Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting

EP: 7.Evolving Treatment Strategies in Early HER2+ Breast Cancer

EP: 8.Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS

EP: 9.Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC

Newsletter